Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 9/20 | 0.37 |
| ▸ | HTR2A | P28223 | 8/20 | 0.37 |
| ▸ | HTR2B | P41595 | 8/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1803126 | 1.00 | TRPV1 (0.42) | TRPV1HTR2CHTR2AHTR2BP2RX7 | |
| SCHEMBL1803127 | 1.00 | TRPV1 (0.42) | TRPV1HTR2CHTR2AHTR2BP2RX7 | |
| SCHEMBL2598991 | 1.00 | TRPV1 (0.42) | TRPV1HTR2CHTR2AHTR2BP2RX7 | |
| SCHEMBL2599020 | 0.83 | HTR1A (0.43) | HTR2CHTR2AHTR2BHTR1A | |
| SCHEMBL1805318 | 0.83 | HTR1A (0.43) | HTR2CHTR2AHTR2BHTR1A | |
| SCHEMBL1805314 | 0.83 | HTR1A (0.43) | HTR2CHTR2AHTR2BHTR1A | |
| SCHEMBL1805317 | 0.83 | HTR1A (0.43) | HTR2CHTR2AHTR2BHTR1A | |
| SCHEMBL1803329 | 0.79 | ADRA2A (0.47) | HTR2CHTR2AHTR2BSLC6A2SLC6A4 | |
| SCHEMBL2598888 | 0.79 | ADRA2A (0.47) | HTR2CHTR2AHTR2BSLC6A2SLC6A4 | |
| SCHEMBL1803327 | 0.79 | ADRA2A (0.47) | HTR2CHTR2AHTR2BSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571353-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2017-08-09 | — | — | EP | claimed |
| US-8846951-B2 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC. (US) | 2014-09-30 | — | — | US | claimed |
| US-20110118231-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-05-19 | — | — | US | claimed |
| EP-2571353-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2017-08-09 | — | — | EP | disclosed |
| US-8846951-B2 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20110118231-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118231-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR3A, HTR5A, HTR3C | TRPV1 222/4885HTR2C 4/4885HTR2A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.